The clinically best established general screening tumor marker at present is prostate-specific antigen (PSA), which is considered a specific indicator of prostate cancer, but still about 15% of 'PSA-negative' men have biopsy-detected prostate cancer [36]. The gene discussed is KLK3; the disease is prostate carcinoma.